HEMATOLOGICAL MALIGNANCIES: LEUKEMIAS, LYMPHOMAS AND MYELOMAS

VolverGo back

Resultados 68 results. LastUpdate Updated on 07/05/2021 [15:21:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Page1/3 nextPage   results/page


METHODS AND COMPOSITIONS FOR PREDICTING AND PREVENTING RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA

Publication No.: US2021128557A1 06/05/2021

Applicant:

MASSACHUSETTS INST TECHNOLOGY [US]
DANA FARBER CANCER INST INC [US]

Absstract of: US2021128557A1

Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof or any combination thereof.

traducir

METHODS FOR TREATMENT OR PREVENTION OF LEUKEMIA

Publication No.: US2021128602A1 06/05/2021

Applicant:

MEMORIAL SLOAN KETTERING CANCER CENTER [US]

WO_2018165482_PA

Absstract of: US2021128602A1

The present disclosure relates generally to methods for preventing, ameliorating or treating leukemia. In particular, the present disclosure relates to administering a therapeutically effective amount of at least one agent to reduce the expression of synaptotagmin-binding, cytoplasmic RNA-interacting protein (SYNCRIP) to a subject diagnosed with, or at risk for acute myeloid leukemia (AML).

traducir

ANTI-TUMOR COMBINATION THERAPY COMPRISING ANTI-CD19 ANTIBODY AND GAMMA DELTA T-CELLS

Publication No.: US2021130461A1 06/05/2021

Applicant:

MORPHOSYS AG [DE]

Absstract of: US2021130461A1

The present disclosure is directed to a combination therapy comprising an anti-CD19 antibody or antibody fragment thereof and gamma delta T-cells (γδ T-cells) for use in the treatment of leukemia or lymphoma.

traducir

ANTI-CD19 THERAPY IN COMBINATION WITH LENALIDOMIDE FOR THE TREATMENT OF LEUKEMIA OR LYMPHOMA

Publication No.: US2021130460A1 06/05/2021

Applicant:

MORPHOSYS AG [DE]

Absstract of: US2021130460A1

The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and lenalidomide for use in the treatment of hematological cancer patients. Furthermore, the present disclosure concerns extending the overall survival and/or the progression free survival in patients having specific types of hematological cancer.

traducir

GENETIC MODIFICATION OF RATS

Publication No.: US2021130846A1 06/05/2021

Applicant:

REGENERON PHARMA [US]

MX_2019015525_A

Absstract of: US2021130846A1

Compositions and methods are provided for making rat pluripotent and totipotent cells, including rat embryonic stem (ES) cells. Compositions and methods for improving efficiency or frequency of germline transmission of genetic modifications in rats are provided. Such methods and compositions comprise an in vitro culture comprising a feeder cell layer and a population of rat ES cells or a rat ES cell line, wherein the in vitro culture conditions maintain pluripotency of the ES cell and comprises a media having mouse leukemia inhibitory factor (LIF) or an active variant or fragment thereof. Various methods of establishing such rat ES cell lines are further provided. Methods of selecting genetically modified rat ES cells are also provided, along with various methods to generate a transgenic rat from the genetically modified rat ES cells provided herein. Various kits and articles of manufacture are further provided.

traducir

COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN TREATING CANCER

Publication No.: US2021130453A1 06/05/2021

Applicant:

MEDIMMUNE LTD [GB]
FUNDACIO PRIVADA INST DINVESTIGACIO ONCOLOGICA DE VALL HEBRON [ES]
FUNDACIO PRIVADA INST CATALANA DE RECERCA I ESTUDIS AVANCATS [ES]

CN_112585164_A

Absstract of: US2021130453A1

Described herein are methods of treating cancer using combinations of Leukemia Inhibitory Factor (LIF)-binding polypeptides and PD-1 axis inhibitors.

traducir

T CELL RECEPTORS FOR IMMUNOTHERAPY

Publication No.: US2021130431A1 06/05/2021

Applicant:

UNIV TEXAS [US]

Absstract of: US2021130431A1

Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind the T-cell leukemia/lymphoma 1 (TCL1) oncoprotein. The TCR may be utilized in various therapies, such as autologous TCL1-TCR adoptive T cell therapy, to treat a cancer, such as a B-cell malignancy or a solid tumor expressing TCL1. Methods for expanding a population of T cells that target TCL1 are also provided.

traducir

BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA

Publication No.: US2021128618A1 06/05/2021

Applicant:

JANSSEN BIOTECH INC [US]

Absstract of: US2021128618A1

Provided herein is a method of treating a subject who has a cancer. At least one dose of chimeric antigen receptor (CAR)-T cells comprising a CAR comprising a polypeptide is administered to the subject. The peptide comprises an extracellular antigen binding domain with at least two BCMA-binding moieties, a transmembrane domain, and an intracellular signaling domain. The dose of CAR-T cells administered to the subject is from 4.0×105 to 1.0×106 of CAR-T cells per kilogram of the subject's mass. Alternatively, the dose comprises 1×106 to 1×108 of the CAR-T cells.

traducir

CONJUNCTIVAL DISEASE DETECTION METHOD USING OCULAR SURFACE TISSUE, AND BIOMARKER FOR AGING

Publication No.: EP3816300A1 05/05/2021

Applicant:

UNIV OSAKA [JP]
OTSUKA PHARMA CO LTD [JP]

WO_2020004626_PA

Absstract of: EP3816300A1

It aims to construct a technology in which the onset or progression of an aging state or a specific disease can be evaluated in an objective and highly reproducible manner, and in particular, to provide a method of detecting conjunctival diseases such as conjunctival MALT lymphoma, and to provide an aging biomarker that serves as an indicator of the aging state.A method of detecting a conjunctival disease using an ocular surface tissue, the method comprising a step of comparing a microbial community structure of a microbiota included in an ocular surface tissue specimen sampled from a healthy person, with a microbial community structure of a microbiota included in an ocular surface tissue specimen sampled from a subject to detect an ocular surface tissue specimen which is sampled from the subject evaluated as having the conjunctival disease based on a change in the microbial community structure between the healthy person and the subject, and an aging biomarker for detecting an aging state, the aging biomarker comprising a bacterial species which belongs to at least one family selected from Corynebacteriaceae family and Propionibacteriales family in an ocular surface tissue.

traducir

CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN

Publication No.: US2021123063A1 29/04/2021

Applicant:

US HEALTH [US]

KR_20210032014_A

Absstract of: US2021123063A1

The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.

traducir

Anti-LAG-3 Antibodies to Treat Hematological Malignancies

Publication No.: US2021122820A1 29/04/2021

Applicant:

SQUIBB BRISTOL MYERS CO [US]

JP_2020015737_A

Absstract of: US2021122820A1

Provided are methods for clinical treatment of hematological malignancies, such as relapsed or refractory chronic lymphocytic leukemia or lymphoma using an anti-LAG-3 antibody. Particular malignancies include, e.g., chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL).

traducir

COMBINATION THERAPY OF A CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY AND A KINASE INHIBITOR

Publication No.: US2021121466A1 29/04/2021

Applicant:

JUNO THERAPEUTICS INC [US]

CN_112584902_A

Absstract of: US2021121466A1

Provided are combination therapies involving immunotherapies e.g., a chimeric antigen receptor (CAR) T cell therapy, and the use of a kinase inhibitor, e.g., a BTK/1TK inhibitor, e.g. Ibrutinib, for treating subjects having cancers, such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The CART cell therapy includes cells that express recombinant receptors such as anti-CD19 CARS. In some embodiments, the B-cell malignancy is a non-Hodgkin lymphoma (NHL), such as relapsed or refractory NHL or specific NHL subtype.

traducir

Anti-lambda myeloma antigen (LMA) binding proteins to treat LMA-expressing cancer and autoimmune disorders

Publication No.: AU2021202092A1 29/04/2021

Applicant:

HAEMALOGIX PTY LTD [AU]

KR_20210005553_A

Absstract of: AU2021202092A1

The present disclosure relates to anti-LMA binding proteins. Such binding proteins may be useful for treating disorders associated with aberrant proliferation of plasma cells and/or their precursors.

traducir

METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA USING 2-(2,6-DIOXOPIPERIDIN-3YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1. 3-DIONE

Publication No.: WO2021080936A1 29/04/2021

Applicant:

CELGENE CORP [US]

US_2021113574_A1

Absstract of: WO2021080936A1

Provided herein are methods of using 2-(2,6-dioxopiperidin-3yl)-4-(2-fluoro-4-(3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiometer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with obinutuzumab, for treating, preventing or managing chronic lymphocytic leukemia/small lymphocytic lymphoma.

traducir

THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF MULTIPLE MYELOMA, LYMPHOMA, AND LEUKEMIA

Publication No.: US2021121437A1 29/04/2021

Applicant:

LOWE HENRY [US]
TOYANG NGEH J [US]

US_2020253918_A1

Absstract of: US2021121437A1

A cannabis-based flavonoid pharmaceutical composition for treatment of multiple myeloma, lymphoma, and leukemia, the composition including any one or more selected from among the group of Cannflavin A, Cannflavin B, Cannflavin C, FBL-03G (Caflanone), Chiysoeriol, Cosmosiin, Flavocannabiside and their derivatives selected from among the group of Geraldol, Rhamnetin, Isorhamnetin, Rhamnazin, or their synthases

traducir

CONDITIONAL-siRNAS AND USES THEREOF IN TREATING ACUTE MYELOID LEUKEMIA

Publication No.: US2021123060A1 29/04/2021

Applicant:

HOPE CITY [US]
CALIFORNIA INST OF TECHN [US]

WO_2019033083_PA

Absstract of: US2021123060A1

Disclosed herein are conditional siRNAs activatable by CBFβ-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.

traducir

COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

Publication No.: WO2021079273A1 29/04/2021

Applicant:

RHIZEN PHARMACEUTICALS AG [CH]

Absstract of: WO2021079273A1

The present invention relates to a method of treatment of acute myeloid leukemia (AML). In one embodiment, the present invention relates to a method of treating acute myeloid leukemia (AML) comprising administering to a subject in need thereof a dihydroorotate dehydrogenase (DHODH) inhibitor, alone in combination with at least one /ms-like tyrosine kinase 3 (FLT-3) inhibitor and/or a DNA polymerase inhibitor.

traducir

TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS

Publication No.: EP3811974A1 28/04/2021

Applicant:

INFINITY PHARMACEUTICALS INC [US]

JP_2019194238_A

Absstract of: EP3811974A1

Provided herein is a PI3K inhibitor, alone or in combination with one or more other therapeutic agents, for use in treating or managing indolent non-Hodgkin's lymphoma (iNHL) in a subject that is, or is identified as, relapsed or refractory to a prior treatment with rituximab and the iNHL is refractory to chemotherapy or radioimmunotherapy (RIP), wherein the PI3K inhibitor is Compound 292 or a pharmaceutically acceptable salt, a hydrate or a solvate thereof. Furthermore the application relates to a PI3K inhibitor, alone or in combination with one or more other therapeutic agents, for use in treating or managing cancer or hematologic malignancy in a subject who developed resistance to a prior treatment, wherein the PI3K inhibitor is Compound 292, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and wherein the prior treatment is a treatment with one or more BTK inhibitors, anti-CD20 antibodies, proteasome inhibitors, or alkylating agents.

traducir

METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA

Publication No.: WO2021076196A1 22/04/2021

Applicant:

GENENTECH INC [US]
HOFFMANN LA ROCHE [CH]
HOFFMANN LA ROCHE [US]

Absstract of: WO2021076196A1

Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma (DLBCL)) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody (such as rituximab) and one or more chemotherapeutic agents (such as gemcitabine and oxaliplatin).

traducir

B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES

Publication No.: WO2021074261A1 22/04/2021

Applicant:

HEIDELBERG PHARMA RES GMBH [DE]

Absstract of: WO2021074261A1

The present application relates to a conjugate comprising an amatoxin, a target-binding moiety wherein the target is CD20, i.e., a CD20-binding moiety, and optionally a linker linking said amatoxin and said CD20-binding moiety. The invention further relates to the synthesis of said conjugate. In addition, the invention relates to a pharmaceutical composition comprising such conjugate, particularly for use in the treatment of B-cell and/or lymphoma associated diseases and/or malignancies.

traducir

METHODS OF DETERMINING WHETHER PATIENTS SUFFERING FROM ACUTE MYELOID LEUKEMIA WILL ACHIEVE A RESPONSE TO AN MYC-TARGETING THERAPY

Publication No.: WO2021074338A1 22/04/2021

Applicant:

INST NAT SANTE RECH MED [FR]
CENTRE NAT RECH SCIENT [FR]
ASSIST PUBLIQUE HOPITAUX PARIS APHP [FR]
UNIV PARIS [FR]

Absstract of: WO2021074338A1

Deciphering the impact of metabolic intervention on response to anticancer therapy represents a path toward improved clinical responses. Here, the inventors identify amino acid-related pathways connected to the folate cycle whose activation predicts sensitivity to MYC-targeting therapies in acute myeloid leukemia (AML). They establish that folate restriction and deficiency of the rate-limiting folate-cycle enzyme, MTHFR ― which exhibits reduced- function polymorphisms in about 10% of Caucasians ― enhance resistance to MYC targeting by BET and CDK7 inhibitors in cell lines, primary patient samples and syngeneic mouse models of AML. Further, this effect is abrogated by supplementation with the MTHFR enzymatic product, CH3-THF. Mechanistically, folate cycle disturbance reduces H3K27/K9 histone methylation, and activates a SPI1 transcriptional program counteracting the effect of BET inhibition. Thus the data provide a rationale for screening MTHFR polymorphisms and the folate cycle status to exclude patients least likely and nominate those most likely to benefit from MYC-targeting therapies.

traducir

TREATMENT OR PREVENTION OF LEUKAEMIA

Publication No.: WO2021074614A1 22/04/2021

Applicant:

VESTLANDETS INNOVASJONSSELSKAP AS [NO]
GOLDING LOUISE [GB]

Absstract of: WO2021074614A1

The present invention provides compounds for use in the treatment or prevention of leukaemia which are based on a 2-amino-[1,1']-bipbenyl or corresponding carbazole scaffold, in particular, it provides the following compounds of formula (I), their stereoisomers, and their pharmaceutically acceptable salts for use in such treatment: (I) (I) wherein: Y is selected from C=0 and -CR9 (in which R9 is H, -OH or -O-alkyl, (e.g, -O-C1-6 alkyl)); Z is selected from C=0 and -CR10 (in which R10 is H, -OH, -O-alkyl, (e.g, -O-C1-6 alkyl) or -O-C(O)RA wherein RA is H or alkyl (e.g. C1-6 alkyl)); R1 is -NO2 or -NR11R12 (wherein R11 and R12 are both H, or R11 is H and R12 is a group of the formula -C(O)RA in which RA is H or alkyl (e.g. C1-6 alkyl)); each of R2, R4, and R6 to R8 are independently selected from H, alkyl (e.g. C1-6 alkyl), -O-alkyl (e.g. -O-C1-6 alkyl), and halogen; R3 and R5 are independently selected from H, -O-alkyl (e.g. -O-C1-6 alkyl), and halogen; or R1 and R8 together form a group NR13 (in which R13 is H, alkyl (e.g. C1-6 alkyl), or a group of the formula -C(O)RA in which RA is H or alkyl (e.g. G1-6 alkyl)); and represents an optional bond between two adjacent carbon atoms in the ring; with the proviso that when Y and Z are both C=O, and R1 and R8 together form a group NR13, at least one of R2 and R3 is other than H or -CH3. Such compounds find particular use in the treatment or prevention of chronic myeloid leukaemia (GML), acute myeloid leukaemia (AML), acute lymphocy

traducir

1,4OXAZEPINO2,3-CQUI NOLI NONE DERIVATIVES AS BLC6 INHIBITORS

Publication No.: WO2021074620A1 22/04/2021

Applicant:

CANCER RESEARCH TECH LTD [GB]
THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL [GB]

Absstract of: WO2021074620A1

The present invention relates to compounds that function as inhibitors of BCL6 (B-cell lymphoma 6) activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

traducir

BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY

Publication No.: WO2021077010A1 22/04/2021

Applicant:

ARVINAS OPERATIONS INC [US]

Absstract of: WO2021077010A1

Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

traducir

COMBINATION THERAPIES FOR TREATING MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA

Nº publicación: WO2021076908A1 22/04/2021

Applicant:

FORTY SEVEN INC [US]

US_2021115140_A1

Absstract of: WO2021076908A1

Methods, kits, and compositions are provided herein that can be used to treat hematopoietic disorders using an anti-CD47 agent such as an antibody and a hypomethylating agent, such as azacitidine.

traducir

Page1/3 nextPage results/page

punteroimgGo back